

# Tuberculosis profile: Venezuela (Bolivarian Republic of)

Population 2019: 29 million

## Estimates of TB burden\*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	13 000 (9 900-16 000)	45 (35-57)
HIV-positive TB incidence	1 000 (320-2 100)	3.5 (1.1-7.4)
MDR/RR-TB incidence**	370 (150-700)	1.3 (0.52-2.4)
HIV-negative TB mortality	750 (720-770)	2.6 (2.5-2.7)
HIV-positive TB mortality	220 (68-460)	0.78 (0.24-1.6)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2019

New cases	2.1% (0.78-4.1)
Previously treated cases	12% (7.4-17)

## Universal health coverage and social protection\*


TB treatment coverage (notified/estimated incidence), 2019	80% (63-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	8% (5-10)

## TB case notifications, 2019

Total new and relapse	10 293
- % tested with rapid diagnostics at time of diagnosis	3.3%
- % with known HIV status	41%
- % pulmonary	86%
- % bacteriologically confirmed ^	78%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2019

(Number)

- % children aged 0-14 years	5%
- % women	32%
- % men	63%
Total cases notified	10 693

## TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	369	8.7%
- on antiretroviral therapy	304	82%

## Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	4.3%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	37%
Laboratory-confirmed cases - MDR/RR-TB ^^	34
Patients started on treatment - MDR/RR-TB ^^	34
Laboratory-confirmed cases - XDR-TB ^^	1
Patients started on treatment - XDR-TB ^^	1
MDR/RR-TB cases tested for resistance to any fluoroquinolone	27

## Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	84%	11 011
Previously treated cases, excluding relapse, registered in 2018	78%	377
HIV-positive TB cases registered in 2018	67%	473
MDR/RR-TB cases started on second-line treatment in 2017	75%	72
XDR-TB cases started on second-line treatment in 2017	50%	2

## TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	1.2%
---	------



## Treatment success rate



## Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	99% (73-100)
---	-----------------

## TB financing

National TB budget, 2020 (US\$ millions)	4
- Funding source, domestic	3.1%
- Funding source, international	41%
- unfunded	56%

\* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

---

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)